Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY4152199 - IV
LY4152199 · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1: Dose Escalation (Cohort A) - DLBCL and FL | EXPERIMENTAL | Escalating doses of LY4152199 administered intravenously (IV) |
| Phase 1: Dose Optimization (Cohort B1) - DLBCL | EXPERIMENTAL | Two or more doses of LY4152199 (evaluated during dose escalation) administered IV |
| Phase 1: Dose Optimization (Cohort B2) - FL | EXPERIMENTAL | Two or more doses of LY4152199 (evaluated during dose escalation) administered IV |
| Name | Type | Description |
|---|---|---|
| LY4152199 - IV | DRUG | Administered by IV infusion |
Inclusion Criteria: * Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma. * Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator. * Par...
LY4152199 is an investigational small molecule being studied for the treatment of previously treated B-cell malignancies, including non-Hodgkin lymphoma. The ongoing clinical trial focuses on conditions such as diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, and mantle cell lymphoma.
LY4152199 targets BAFF-R, a protein involved in B-cell survival and maturation. By targeting BAFF-R, the drug is designed to interfere with signaling pathways that support the growth and survival of malignant B-cells, which are central to the development of B-cell lymphomas and related blood cancers.
LY4152199 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy in patients with previously treated B-cell malignancies.
LY4152199 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial is actively recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy in patients with B-cell malignancies.
LY4152199 is being evaluated in a Phase 1 clinical trial with the identifier NCT07101328, titled "A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1)." This randomized, controlled trial is recruiting approximately 215 participants across multiple countries, including the United States, Australia, Canada, and several European and Asian nations.
Yes, LY4152199 is also known as LY4152199 - IV, which refers to the intravenous formulation of the drug. The clinical trial NCT07101328 is evaluating this intravenous form of LY4152199 in patients with previously treated B-cell malignancies.